PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors-Reference-Cited by-同舟云学术

PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors

Published:2021-10-06 Issue:6 Volume:27 Page:911-920
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Escobar Miguel¹^ORCID,Luck James²,Averianov Yevhenii³,Ducore Jonathan⁴,Fernández Maria Fernanda López⁵,Giermasz Adam⁶,Hart Daniel P.⁷,Journeycake Janna⁸,Kessler Craig⁹^ORCID,Leissinger Cindy¹⁰,Mahlangu Johnny¹¹^ORCID,Martinez Laura Villarreal¹²^ORCID,Miesbach Wolfgang¹³^ORCID,Mitha Ismail Haroon¹⁴,Quon Doris²,Reding Mark T.¹⁵^ORCID,Schved Jean‐François¹⁶,Stasyshyn Oleksandra¹⁷,Vilchevska Kateryna V.¹⁸,Wang Michael¹⁹^ORCID,Windyga Jerzy²⁰^ORCID,Alexander W. Allan²¹,Al‐Sabbagh Ahmad²²,Bonzo Daniel²²^ORCID,Mitchell Ian S.²³^ORCID,Wilkinson Thomas A.²⁴,Hermans Cédric²⁵

Affiliation:

1. Gulf States Hemophilia and Thrombophilia Center Houston Texas USA

2. Orthopaedic Hemophilia Treatment Center Los Angeles California USA

3. City Research and Development Center for Diagnostics and Treatment of Patients with Abnormal Hemostasis Kyiv Ukraine

4. Hematology/Oncology Clinic University of California at Davis Sacramento California USA

5. Hemostasis and Thrombosis Unit Teresa Herrera Hospital A Coruña Spain

6. Division of Hematology/Oncology University of California at Davis Sacramento California USA

7. The Royal London Hospital Haemophilia Centre Barts and The London School of Medicine and Dentistry, QMUL London UK

8. Oklahoma Center for Bleeding and Clotting Disorders Oklahoma City Oklahoma USA

9. Lombardi Comprehensive Cancer Center Georgetown University Medical Center Washington District of Columbia USA

10. Section of Hematology/Oncology Tulane University School of Medicine New Orleans Louisiana USA

11. Hemophilia Comprehensive Care Center University of the Witwatersrand and National Health Laboratory Service Johannesburg South Africa

12. Dr. José Eleuterio González Monterrey University Hospital Monterrey Nuevo León México

13. Goethe University Hospital Frankfurt Germany

14. Lakeview Hospital Benoni Gauteng South Africa

15. Center for Bleeding and Clotting Disorders University of Minnesota Medical Center Minneapolis Minnesota USA

16. Haemophilia Treatment Centre University Hospital Montpellier Montpellier France

17. Institute of Blood Pathology and Transfusion Medicine Lviv Ukraine

18. National Specialized Children's Hospital Okhmatdyt Kyiv Ukraine

19. Hemophilia and Thrombosis Center University of Colorado Aurora Colorado USA

20. Department of Hemostasis Disorders and Internal Medicine Institute of Hematology and Transfusion Medicine Warsaw Poland

21. Aoede Associates Athens Texas USA

22. LFB‐USA, Inc. Framingham Massachusetts USA

23. HEMA Biologics, LLC Louisville Kentucky USA

24. GLOVAL LLC Broomfield Colorado USA

25. Cliniques Saint‐Luc Université Catholique de Louvain Brussels Belgium

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14418

Reference30 articles.

1. The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors

2. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study

3. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents

4. Impact of inhibitors on hemophilia a mortality in the United States

5. Effect of Acute Bleeding on Daily Quality of Life Assessments in Patients with Congenital Hemophilia with Inhibitors and Their Families: Observations from the Dosing Observational Study in Hemophilia

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Haemophilia in the era of novel therapies: Where do inhibitors feature in the new landscape?;Haemophilia;2024-03-27

2. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective;Haemophilia;2024-02-05

3. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors;Expert Review of Hematology;2023-09-25

4. Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders;Annals of Hematology;2023-06-30

5. Time is Blood: The Impact of Diagnostic Delays on Acquired Hemophilia A;Cureus;2022-02-09